Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| LEXICON PHARMACEUTICALS, INC.LXRX · Entity 4970 | Director · Chief Executive Officer | February 28, 2026 | March 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
LEXICON PHARMACEUTICALS, INC.
Report date February 28, 2026 · Filed March 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 298,432 |
Ending reported balance
After 2026-02-28 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-02-28 · Exercise / conversion · Acquired 503,263 · Balance 503,263 F1: Each restricted stock unit represents a contingent right to receive one share of common stock. Row 2 · 2026-02-28 · Tax withholding · Disposed 204,831 · Balance 298,432 F2: Withholding of a portion of issued shares by the Company in satisfaction of shareholder's tax withholding obligations with respect thereto. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 1,006,527 |
Reported balance
After 2026-02-28 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-02-28 · Exercise / conversion · Disposed 503,263 · Balance 1,006,527 F1: Each restricted stock unit represents a contingent right to receive one share of common stock. F3: Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of common stock.
F2: Withholding of a portion of issued shares by the Company in satisfaction of shareholder's tax withholding obligations with respect thereto.
F3: Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 28, 2026 Filed Mar 3, 2026 12:15 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | Exercise / conversionRestricted Stock Units · Derivative | 503,263 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001062822-26-000034 · form4.xml · derivative · entry 3 Exton Michael · CIK 0002029249 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,006,527 Underlying: Common Stock · 503,263 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. F3 · derivative.exercise_date: Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant. F3 · derivative.expiration_date: Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant. Read SEC document |
| February 28, 2026 Filed Mar 3, 2026 12:15 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | Tax withholdingCommon Stock | 204,831 | $1.47 | $301,101.57 |
DisclosureSEC source: 0001062822-26-000034 · form4.xml · nonDerivative · entry 2 Exton Michael · CIK 0002029249 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 298,432 F2 · kind: Withholding of a portion of issued shares by the Company in satisfaction of shareholder's tax withholding obligations with respect thereto. Read SEC document |
| February 28, 2026 Filed Mar 3, 2026 12:15 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | Exercise / conversionCommon Stock | 503,263 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001062822-26-000034 · form4.xml · nonDerivative · entry 1 Exton Michael · CIK 0002029249 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 503,263 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. Read SEC document |
| February 12, 2026 Filed Feb 17, 2026 21:05 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | GrantStock Option (Right to Buy) · Derivative | 1,293,670 | $0.00 Strike: $1.37 | $0.00 |
DisclosureSEC source: 0001062822-26-000019 · form4.xml · derivative · entry 2 Exton Michael · CIK 0002029249 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,293,670 Underlying: Common Stock · 1,293,670 shares Expires 2036-02-12 F3 · derivative.exercise_date: Option vests with respect to 25% of the shares subject to the option on the first anniversary of grant, and vests 1/48th per month for each month of service thereafter. Read SEC document |
| February 12, 2026 Filed Feb 17, 2026 21:05 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | GrantRestricted Stock Units · Derivative | 862,440 | $0.00 | $0.00 |
DisclosureSEC source: 0001062822-26-000019 · form4.xml · derivative · entry 1 Exton Michael · CIK 0002029249 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 862,440 Underlying: Common Stock · 862,440 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F2 · derivative.exercise_date: Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant. F2 · derivative.expiration_date: Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant. Read SEC document |
| February 13, 2025 Filed Feb 18, 2025 21:16 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | GrantRestricted Stock Units · Derivative | 1,509,790 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-005209 · form4.xml · derivative · entry 2 Exton Michael · CIK 0002029249 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,509,790 Underlying: Common Stock · 1,509,790 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F3 · derivative.exercise_date: Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant. F3 · derivative.expiration_date: Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant. Read SEC document |
| February 13, 2025 Filed Feb 18, 2025 21:16 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | GrantStock Option (Right to Buy) · Derivative | 2,264,690 | $0.00 Strike: $0.70 | $0.00 |
DisclosureSEC source: 0001127602-25-005209 · form4.xml · derivative · entry 1 Exton Michael · CIK 0002029249 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,264,690 Underlying: Common Stock · 2,264,690 shares Expires 2035-02-13 F1 · derivative.exercise_date: Option vests with respect to 25% of the shares subject to the option on the first anniversary of grant, and vests 1/48th per month for each month of service thereafter. Read SEC document |
| July 08, 2024 Filed Jul 8, 2024 21:27 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | GrantStock Option (Right to Buy) · Derivative | 1,675,000 | $0.00 Strike: $1.67 | $0.00 |
DisclosureSEC source: 0001127602-24-020202 · form4.xml · derivative · entry 1 Exton Michael · CIK 0002029249 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,675,000 Underlying: Common Stock · 1,675,000 shares Expires 2034-07-08 F1 · derivative.exercise_date: Option vests with respect to 25% of the shares subject to the option on the first anniversary of grant, and vests 1/48th per month for each month of service thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.